SCHEMBL3309641

SCHEMBL3309641

COc1cccc(-c2cc(OC3CC4C(=O)NC(C(=O)O)CCC=CCCCCN(C)C(=O)C4C3)nc(OC)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 1/20 0.45
▸ CTSS P25774 1/20 0.35
▸ NEK2 P51955 1/20 0.34
▸ BACE1 P56817 2/20 0.33
▸ PTGDR Q13258 1/20 0.33
▸ VCP P55072 1/20 0.33
▸ PDE10A Q9Y233 1/20 0.32
▸ AVPR1B P47901 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ MAPT P10636 3/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ LMNA P02545 2/20 0.32
▸ TP53 P04637 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ WDR5 P61964 2/20 0.32
▸ UCHL1 P09936 1/20 0.31
▸ USP30 Q70CQ3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3309948 0.94 CTSB (0.45) CTSBCTSSMAPTTSHRFFAR2
SCHEMBL3315190 0.92 CTSB (0.45) CTSBCTSSNEK2PTGDRVCP
SCHEMBL3308309 0.87 CTSB (0.38) CTSBCTSS
SCHEMBL3309557 0.86 CTSB (0.43) CTSBCTSSMAPTALDH1A1LMNA
SCHEMBL16628839 0.86 CTSB (0.44) CTSBCTSSALDH1A1MAPK1
SCHEMBL3309377 0.84 CTSB (0.41) CTSBCTSSMAPTALDH1A1LMNA
SCHEMBL3310240 0.84 CTSB (0.42) CTSBCTSSFFAR2
SCHEMBL3311656 0.84 CTSB (0.36) CTSBCTSS
SCHEMBL3309647 0.83 CTSB (0.58) CTSBCTSSBACE1PTGDRMAPT
SCHEMBL13330964 0.83 CTSB (0.58) CTSBCTSSBACE1PTGDRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118091-B1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS JANSSEN SCIENCES IRELAND UC (IE) 2015-04-15 — — EP disclosed
US-8937080-B2 Pyrimidine substituted macrocyclic HCV inhibitors MEDIVIR AB (SE) 2015-01-20 — — US disclosed
US-20100113440-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS TIBOTEC PHARMACEUTICALS, LTD. (IE) 2010-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113440-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS NUDT1, PNP, SLC28A1 CTSB 2141/4885CTSS 1936/4885NEK2 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback